KBTBD13

Across TCGA pan-cancer cohorts, KBTBD13 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KBTBD13 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher KBTBD13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KBTBD13 expression acts as an unfavorable survival marker.

SCLC and LUSC are the cancer types where KBTBD13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.192	0.793	.017	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

KBTBD13–SCLC (DFS)

Open the SCLC breakdown →